Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026 Featuring 767 Cell Therapies in the Clinical Pipeline & 25 Marketed Cell Therapies - ResearchAndMarkets.com

May 24, 2019

DUBLIN--(BUSINESS WIRE)--May 24, 2019--

The “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” report has been added to ResearchAndMarkets.com’s offering.

“Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights

In recent years, there has been a steady increase in the interest shown in the cell therapy segment from big pharmaceutical, biotech and medical device companies. Earlier, the idea for altering a cell or a gene to cure or treat disease was considered impossible. But with the ongoing advancements, it has now become possible in the treatment or cure of a disease with the help of cell therapy.

Cell therapies are still in the early stages of clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell-based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that consideration will be given on how these therapies will be carried out and subsequently be delivered to the patients on a clinical relevancy scale.

Currently, there are more than 750 cell-based therapies in the clinical pipeline. Most of the cell therapies are in Preclinical phase followed by Phase-I clinical trials. Analysis of the pipeline shows that the majority of the cell therapy products that are currently under development are targeted towards treatment of complex disease like cardiovascular disease, neural disease and cancer. More than 20 cell therapies are commercially available in the market. However, when it comes to marketed products, more than half of the products that are currently available are in the tissue and skin treatment segment such as Apligraf and Dermigraf.

Few cell therapy products such as Kymriah, Provenge and Yescarta have emerged as the most promising therapeutics of the decade with excellent result in treatment of various clinical indications, but the market remains widely untapped due to the high price tag.

The cell therapy technique finds wide usage in almost all types of therapeutic areas. However, the majority of the cell therapy research is currently being done in cancer, Neurological, Cardiovascular and Inflammatory segments due to their high mortality rate among the global population. Few cell therapy research is being done in the diabetic segment too where the aim is to develop an artificial pancreas using cell therapy which would work just like a natural pancreas.

Cell therapies will also have the potential to replace many risky, costly and invasive surgeries. For many disease conditions, such as diabetes, patients are required to take a prescription on a daily basis. A cell therapy approach will substantially reduce the healthcare costs of this disease by providing a one-time treatment. In the same way cell therapy approaches to pain management will also reduce the costs of opioid-based pain medications. Cell therapy, in combination with the recent advances in iPS cell generation and CRISPR-Cas 9, also has a great opportunity in the future.

The path towards the success for cell therapy will consist of a combination of scenarios that is being imagined for the cure of diseases and is hoped that these will definitely come true in the near future. The advantages and risks of current cell therapy practices will improve translational success and accelerate the clinical development of safe and efficient cell products in the future.

Key Topics Covered:

1. Overview of Cell Therapy

1.1 Introduction to Cell Therapy

1.2 History & Evolution of Cell Therapy

2. Types of Cell Therapy

2.1 Allogeneic Cell Therapy

2.2 Autologous Cell Therapy

2.3 Human Embryonic Stem Cell Therapy

2.4 Neural Stem Cell Therapy

2.5 Mesenchymal Stem Cell Therapy

2.6 Hematopoietic Stem Cell Transplantation

3. Mechanism of Therapeutic Action in Cell Therapy

4. Manufacturing of Cell Therapies

4.1 Models for Manufacturing Cell Therapies

4.2 Facilities for Good Manufacturing Practice

5. Advantages of Cell Therapy Over Conventional Therapy

5.1 Anti-Aging with Cell Therapy

5.2 Addressing Other Diseases with Cell Therapy

6. Personalized Cell Therapy

6.1 Overview of Personalized Cell Therapy

6.2 Personalized Cell Therapy Using Epigenetic Tools

6.3 Personalized Cell Therapy through Mesenchymal Stem Cells

6.4 Treatment of Parkinson’s Disease through IPSCs

6.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp Stem Cells & Leukocyte Platelet Rich Fibrin

7. Cell Therapy Application by Therapeutic Areas

7.1 Cardiovascular Disease

7.2 Neurological Disorders

7.3 Inflammatory Diseases

7.4 Diabetes

7.5 Cancer

8. Global Cell Therapy Market Outlook

8.1 Current Market Scenario

8.2 Cell Therapy Market by Cell Source

8.2.1 Induced Pluripotent Stem Cell (IPSCs)

8.2.2 Bone Marrow

8.2.3 Umbilical Cord Blood Derived Cells

8.3 Global Cell Therapy Clinical Pipeline (Company,Indication, Region) Overview

9. US - Cell Therapy Dosage & Cost Analysis

9.1 Allocord

9.2 Laviv

9.3 Maci

9.4 Clevecord

9.5 Hemacord

9.6 Ducord

9.7 Provenge

9.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)

9.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)

9.10 HPC, Cord Blood (Bloodworks)

9.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)

9.12 Gintuit

9.13 Kymriah*

9.14 Yescarta*

9.15 Carticel

10. South Korea - Cell Therapy Dosage & Cost Analysis

10.1 Cartistem

10.2 Chondron

10.3 KeraHeal

10.4 Cellgram

10.5 Cure Skin Injection

11. Australia, Europe & Japan - Cell Therapy Dosage & Cost Analysis

11.1 Holoclar (Europe)

11.2 Yescarta (EU)

11.3 Kymriah (EU)

11.4 Temcell HS (Japan)

11.5 Chondrocytes-T-Ortho-ACI (Australia)

12. Cell Therapy Market Trends: Geographically

12.1 US

12.2 South Korea

12.3 Europe

12.4 Japan

12.5 China

12.6 Rest of the World

12.6.1 Africa

12.6.2 Middle East

12.6.3 South America

13. Advancements in Cell Therapy

13.1 Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia

13.2 Advances in Cytomegalovirus Infection Prevention & Treatment

13.3 Stem Cell Therapy for the Treatment of Parkinson’s Disease

13.4 Stem Cell Therapy for the Treatment of Alzheimer’s Disease

13.5 Treatment of Rheumatoid Arthritis via Stem Cell Therapy

13.6 Role of Stem Cell Therapy in Treating Infertility

13.7 Stem Cells for Eye Diseases

13.8 Cell Therapy for Stroke and Angina Pectoris

13.9 Stem Cell Therapy in Improving Wrinkles & Acne Scars

14. Treg Cells - The Next Edge of Cell Therapy

14.1 Introduction to Treg Cell

14.2 Isolation & Expansion of Treg Cell

14.3 Mechanism of Action

14.4 Clinical Trials of Treg Cell Therapy

14.4.1 Adoptive Cell Therapy of Treg cells to Prevent GvHD

14.4.2 Adoptive Cell Therapy of Polyclonal & Alloantigen-specific Treg cells to Prevent Solid Organ Transplant Rejection

14.5 Treg Cell Therapy for the Treatment of Autoinflammatory & Autoimmune Diseases

14.5.1 Inflammatory Bowel Disease

14.5.2 Systemic Lupus Erythematosus

14.5.3 Autoimmune Hepatitis

14.5.4 Pemphigus Vulgaris

14.5.5 Allergy and Asthma

14.6 Future Prospects of Treg Cell Therapy

15. Global Cell Therapy Market Dynamics

15.1 Market Drivers

15.2 Commercial Challenges

16. Global Cell Therapy Market Future Prospects

17. Marketed Cell Therapies Clinical Insight by Company & Indication

17.1 Tisagenlecleucel (Kymriah)

17.2 Axicabtagene Ciloleucel (Yescarta)

17.3 Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)

17.4 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)

17.5 Tonogenchoncel-L (INVOSSA-K inj)

17.6 Mesenchymal Stem Cell Therapies (Stempeucel)

17.7 Remestemcel-L (Prochymal & TEMCELL HS Inj.)

17.8 Sipuleucel-T (Provenge)

17.9 Autologous Mesenchymal Stem Cell Therapy - Pharmicell

17.10 Autologous Cultured Chondrocytes (MACI)

17.11 Autologous Cultured Chondrocytes (Chondrotransplant DISC)

17.12 Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)

17.13 Nalotimagene Carmaleucel (Zalmoxis)

17.14 Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)

17.15 Autologous Chondrocyte Implant - TETEC

17.16 Muscle-Derived Autologous Stem Cell Therapy (MyoCell)

17.17 Human Skin Replacement (CellSpray)

17.18 Leukocyte Cell Therapy (CureXcell)

17.19 Autologous Cultured Chondrocyte Implant (Carticel)

17.20 Azficel-T (Laviv)

17.21 Autologous Cultured Chondrocytes (CHONDRON)

17.22 Autologous Chondrocytes (BioCart)

17.23 Amniotic Cell Therapy (NuCel)

17.24 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

17.25 Autologous Cultured Myoblasts And Fibroblasts (Urocell)

18. Global Cell Therapy Clinical Pipeline by Company, Indication & Phase

18.1 Research

18.2 Preclinical

18.3 Clinical

18.4 Phase-0

18.5 Phase-I

18.6 Phase-I/II

18.7 Phase-II

18.8 Phase-II/III

18.9 Phase-III

18.10 Preregistration

18.11 Registered

19. Competitive Landscape

19.1 Athersys Inc.

19.2 Baxter Healthcare Corporation

19.3 Bone Therapeutics

19.4 Celgene Corporation

19.5 Cell Medica

19.6 Cellerant Therapeutics

19.7 FibrocellScinence

19.8 Genzyme Corporation

19.9 Green Cross Cell

19.10 Histogenics Corporation

19.11 Intrexon Corporation

19.12 Intercytex

19.13 ISTO Biologics

19.14 Macrocure

19.15 Mesoblast

19.16 Molmed

19.17 Nuo Therapeutics Inc

19.18 OmniCyte

19.19 Opexa Therapeutics

19.20 Organogenesis

19.21 Pharmicell

19.22 TCA Cellular Therapy

19.23 Stem Cell Inc.

19.24 Teva Pharmaceuticals

19.25 Tigenix

19.26 Vericel Corporation

For more information about this report visit https://www.researchandmarkets.com/r/d51vww

View source version on businesswire.com:https://www.businesswire.com/news/home/20190524005193/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics,Clinical Trials



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/24/2019 09:32 AM/DISC: 05/24/2019 09:32 AM


All contents © copyright 2019 The Associated Press. All rights reserved.